<DOC>
	<DOCNO>NCT02861287</DOCNO>
	<brief_summary>This study aim realize economic evaluation introduction Plerixafor addition G-CSF alternative option , patient multiple myeloma ( MM ) fail insufficiently mobilize peripheral blood stem progenitor cell response G-CSF alone .</brief_summary>
	<brief_title>Economic Evaluation Use Plerixafor Autologous HSC Transplantation Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<criteria>Adult patient diagnose Multiple Myeloma eligible highdose melphalan support autologous hematopoietic stem cell transplantation ( HSCT ) part treatment plan First mobilization attempt `` rhGCSF alone '' mobilization regimen Failed mobilization document increase CD34+ cell mobilization deem insufficient initiate apheresis ( 15/ÂµL ) , 4 first injection rhGCSF administer evening Age &lt; 18 year ; Primary diagnosis MM 2nd subsequent mobilization attempt Patients previously receive HDCT + autologous HSCT Chemotherapybased mobilization regimen Efficient mobilization , allow apheresis collection target cell number ( 5x106 CD34+ cells/kg every plan autologous transplantation per institutional SOPs ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>